[ANSWER]HSNS365 A2 Case Study: Comprehensive Case Study
[ANSWER PREVIEW] Which in turn widens blood vessels, reduces contraction in the myocardium, and Comprehensive Case Study.
The pharmacological management of NSTEMI involves a combination of statins, nitrates, beta blockers, antiplatelets, P2Y12 inhibitors, glycoprotein IIb/IIIa inhibitors, and anti-coagulants (Anantharaman & Lim, 2013). These medications help in alleviating ischaemia, preventing additional thrombosis Comprehensive Case Study, as well as stabilising haemodynamic and electrical activity in the heart (Gambhir, 2018). Glyceryl trinitrate (GTN), also known as nitroglycerin, is one of the major medications for treating chest pain associated with NSTEMI (Kumar & Cannon, 2009).
The efficacy of GTN as a first-line intervention for relieving chest pain is well supported by empirical evidence (Giuseppe, Paul & Hans-Ulrich, 2015; Ferreira & Mochly-Rosen, 2012; Smeeth et al., 2010). GTN is converted in the smooth muscle cells into nitric oxide, which in turn activates guanylate cyclise and cyclic guanosine monophosphate (Ferreira & Mochly-Rosen, 2012). This activation relaxes vascular smooth muscles, resulting in vasodilation and increased flow of blood to the myocardium Comprehensive Case Study.
These processes eventually relieve chest pain in NSTEMI patients. Even so, it is vital to note that continuous GTN administration may lead to tolerance due to ALDH 2 (aldehyde dehydrogenase) activation (Ferreira & Mochly-Rosen, 2012). This is one of the major shortcomings of GTN as a treatment for NSTEMI. David’s treatment regimen also included amlodipine and metoprolol. Amlodipine is a calcium antagonist that is effective in providing chest pain relief in NSTEMI patients (Kumar & Cannon, 2009). The medication achieves this by slowing down calcium transport, which in turn widens blood vessels, reduces contraction in the myocardium, and Comprehensive Case Study..[Buy Full Answer for Just USD 9: 2425 WORDS]
[SOLUTION DESCRIPTION]
Type: Essay
Word Count: 2425
Grade/Mark: 93 (Distinction)